Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Expression of CCL9/MIP-1γ is repressed by BCR/ABL and its restoration suppresses in vivo leukemogenesis of 32D-BCR/ABL cells

Oncogene volume 26, pages 3482–3491 (2007)Cite this article

Abstract

Transformation of hematopoietic cells by the BCR/ABL oncogene is caused by perturbation of signal transduction pathways leading to altered patterns of gene expression and activity. By oligonucleotide microarray hybridization of polysomal RNA of untreated and STI571-treated 32D-BCR/ABL cells, we identified the β-chemokine CCL9 as a gene regulated by BCR/ABL in a tyrosine kinase-dependent manner. BCR/ABL repressed CCL9 expression at the transcriptional level by mechanisms involving suppression of p38 MAP kinase, and modulation of the activity of CDP/cut and C/EBPα, two transcription regulators of myeloid differentiation. However, repression of C/EBP-dependent transcription did not prevent the induction of CCL9 expression by STI571, suggesting that C/EBPα is involved in maintaining rather than in inducing CCL9 expression. Restoration of CCL9 expression in 32D-BCR/ABL cells had no effect on the in vitro proliferation of these cells, but reduced their leukemogenic potential in vivo, possibly by recruitment of CD3-positive immune cells. Together, these findings suggest that downregulation of chemokine expression may be involved in BCR/ABL-dependent leukemogenesis by altering the relationship between transformed cells and the microenvironment.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Barberis A, Superti-Furga G, Busslinger M . (1987). Mutually exclusive interaction of the CCAAT-binding factor and of a displacement protein with overlapping sequences of a histone gene promoter. Cell 50: 347–359.

    Article  CAS  PubMed  Google Scholar 

  • Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D . (1986). The chronic myelogenous leukemia-specific p210 protein is the product of the bcr-abl hybrid gene. Science 233: 212–216.

    Article  CAS  PubMed  Google Scholar 

  • Berahovich RD, Miao Z, Wang Y, Premack B, Howard MC, Schell TJ . (2005). Proteolytic activation of alternative CCR1 ligands in inflammation. J Immunol 174: 7341–7351.

    Article  CAS  PubMed  Google Scholar 

  • Daley GQ, Baltimore D . (1988). Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific p210 bcr/abl protein. Proc Natl Acad Sci USA 85: 9312–9316.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Daley GQ, van Etten RA, Baltimore D . (1990). Induction of chronic myelogenous leukemia in mice by the p210bcr/abl gene of the Philadelphia chromosome. Science 247: 824–830.

    Article  CAS  PubMed  Google Scholar 

  • Dean JLE, Sully G, Clark AR, Saklatvala J . (2004). The involvement of AU-rich element-binding proteins in p38 mitogen-activated protein kinase pathway-mediated mRNA stabilization. Cell Signal 16: 1113–1121.

    Article  CAS  PubMed  Google Scholar 

  • Deininger MW, Goldman JM, Melo JV . (2000). The molecular biology of chronic myeloid leukemia. Blood 96: 3343–3356.

    CAS  PubMed  Google Scholar 

  • Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. (2001). Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344: 1038–1042.

    Article  CAS  PubMed  Google Scholar 

  • Eaves C, Cashman J, Wolpe S, Eaves A . (1993). Unresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflammatory protein 1 alpha, an inhibitor of primitive normal hematopoietic cells. Proc Natl Acad Sci USA 90: 12015–12019.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Elefanty AG, Hariharan IK, Cory S . (1990). Bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J 9: 1069–1078.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ferrari-Amorotti G, Keeshan K, Zattoni M, Guerzoni C, Iotti G, Cattelani S et al. (2006). Leukemogenesis induced by wild type and STI571-resistant BCR/ABL is potently suppressed by C/EBPα. Blood 108: 1353–1362.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Friedman AD, Landschulz WH, McKnight SL . (1989). CCAAT/enhancer-binding protein activates the promoter of the serum albumin gene in cultured hepatoma cells. Genes Dev 3: 1314–1322.

    Article  CAS  PubMed  Google Scholar 

  • Geay J-F, Buet D, Zhang Y, Foudi A, Jarrier P, Berthebaud M et al. (2005). p210BCR/ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and downregulation of CXCR4 expression. Cancer Res 65: 2676–2683.

    Article  CAS  PubMed  Google Scholar 

  • Guerzoni C, Bardini M, Mariani SA, Ferrari-Amorotti G, Neviani P, Panno ML et al. (2006). Inducible activation of C/EBPβ, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BCR/ABL-expressing cells. Blood 107: 4080–4089.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hara T, Bacon KB, Cho LC, Yoshimura A, Morikawa Y, Copeland NG et al. (1995). Molecular cloning and functional characterization of a novel member of the C-C chemokine family. J Immunol 155: 5352–5358.

    CAS  PubMed  Google Scholar 

  • Johnson D, Agochiya M, Samejima K, Earnshaw W, Frame M, Wyke J . (2000). Regulation of both apoptosis and cell survival by v-SRC oncoprotein. Cell Death Differ 8: 685–690.

    Article  Google Scholar 

  • Jongen-Lavrencic M, Salesse S, Delwel R, Verfaillie CM . (2005). BCR/ABL-mediated downregulation of genes implicated in cell adhesion and motility leads to impaired migration toward CCR7 ligands CCL19 and CCL21 in primary BCR/ABL-positive cells. Leukemia 19: 373–380.

    Article  CAS  PubMed  Google Scholar 

  • Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M . (1993). Chronic myelogenous leukemia: a concise update. Blood 82: 691–703.

    CAS  PubMed  Google Scholar 

  • Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. (2002). Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346: 645–652.

    Article  CAS  PubMed  Google Scholar 

  • Khanna-Gupta A, Zibello T, Sun H, Gaines P, Berliner N . (2003). Chromatin immunoprecipitation (ChIP) studies indicate a role for CCAAT enhancer binding proteins alpha and epsilon (C/EBPα and C/EBPɛ) and CDP/cut in myeloid maturation-induced lactoferrin gene expression. Blood 101: 3460–3468.

    Article  CAS  PubMed  Google Scholar 

  • Konopka JB, Watanabe SM, Witte ON . (1984). An alteration of the human c-Abl protein in K562 leukemia cells unmarks associated tyrosine kinase activity. Cell 37: 1035–1042.

    Article  CAS  PubMed  Google Scholar 

  • Lane CM, Guo XY, Macaluso LH, Yung KC, Deisseroth AB . (1999). Presence of p210bcr/abl is associated with decreased expression of a beta chemokine C10 gene in a p210bcr/abl-positive myeloid leukemia cell line. Mol Med 5: 55–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lawson ND, Khanna-Gupta A, Berliner N . (1998). Isolation and characterization of the cDNA for mouse neutrophil collagenase: demonstration of shared negative regulatory pathways for neutrophil secondary granule protein gene expression. Blood 91: 2517–2524.

    CAS  PubMed  Google Scholar 

  • McLaughlin J, Chianese E, Witte ON . (1987). In vitro transformation of immature hematopoietic cells by the p210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci USA 84: 6558–6562.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mohamadzadeh M, Poltorak AN, Bergstresser PR, Beutler B, Takashima A . (1996). Dendritic cells produce macrophage inflammatory protein-1 γ, a new member of the CC chemokine family. J Immunol 156: 3102–3106.

    CAS  PubMed  Google Scholar 

  • Nepveu A . (2001). Role of the multifunctional CDP/Cut/Cux homeodomain transcription factor in regulating differentiation, cell growth and development. Gene 270: 1–15.

    Article  CAS  PubMed  Google Scholar 

  • Okuda K, Golub TR, Gilliland DG, Griffin JD . (1996). p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Oncogene 13: 1147–1152.

    CAS  PubMed  Google Scholar 

  • Parmar S, Katsoulidis E, Verma A, Li Y, Sassano A, Lal L et al. (2004). Role of the p38-mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR/ABL-expressing cells. J Biol Chem 279: 25345–25352.

    Article  CAS  PubMed  Google Scholar 

  • Pear WS, Miller JP, Xu L, Pui JC, Soffer B, Quackenbush RC et al. (1998). Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210bcr/abl-transduced bone marrow. Blood 92: 3780–3792.

    CAS  PubMed  Google Scholar 

  • Perrotti D, Cesi V, Trotta R, Guerzoni C, Santilli G, Campbell K et al. (2002). BCR-ABL suppresses C/EBPα expression through inhibitory action of hnRNP E2. Nature Gen 30: 48–58.

    Article  CAS  Google Scholar 

  • Pierce A, Spooncer E, Ainsworth S, Wetton AD . (2002). BCR/ABL alters the proliferation and differentiation response of multipotent hematopoietic cells to stem cell factor. Oncogene 21: 3068–3075.

    Article  CAS  PubMed  Google Scholar 

  • Poltorak AN, Buzzoni F, Smirnova I, Alejos E, Thompson P, Luheshi G et al. (1995). MIP-1 γ: molecular cloning, expression, and biological activities of a novel CC chemokine that is constitutively secreted in vivo. J Inflamm 45: 207–219.

    CAS  PubMed  Google Scholar 

  • Ptasznik A, Urbanowska E, Chinta S, Costa MA, Katz BA, Stanislaus MA et al. (2002). Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells. J Exp Med 196: 667–678.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Salgia R, Quackenbush E, Lin J, Souchkova N, Sattler M, Ewaniuk DS et al. (1999). The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1. Blood 94: 4233–4246.

    CAS  PubMed  Google Scholar 

  • Sattler M, Griffin JD . (2003). Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 40: 4–10.

    Article  CAS  PubMed  Google Scholar 

  • Sawyers CL . (1999). Chronic myeloid leukemia. N Engl J Med 340: 1330–1340.

    Article  CAS  PubMed  Google Scholar 

  • Schuster C, Forster K, Darks H, Elsässer A, Behre G, Simon N et al. (2003). The effect of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl Kinase inhibitor imatinib melsylate. Blood 101: 655–663.

    Article  CAS  PubMed  Google Scholar 

  • Tavor S, Park DJ, Gary S, Vuong PT, Gombart AF, Koeffler HP . (2003). Restoration of C/EBPα expression in a BCR/ABL+ cell line induces terminal granulocytic differentiation. J Biol Chem 278: 52651–52659.

    Article  CAS  PubMed  Google Scholar 

  • Wang Q, Friedman AD . (2002). CCAAT/enhancer-binding proteins are required for granulopoiesis independent of their induction of the granulocyte colony-stimulating factor receptor. Blood 8: 2776–2785.

    Article  Google Scholar 

  • Wark G, Heyworth C, Spooncer E, Czaplewski L, Francis J, Dexter T et al. (1998). Abl protein kinase abrogates the response of multipotent hematopoietic cells to the growth inhibitor macrophage inflammatory protein-1 alpha. Oncogene 16: 1319–1324.

    Article  CAS  PubMed  Google Scholar 

  • Wong S, McLaughlin J, Cheng D, Witte ON . (2003). Cell context-specific effects of the BCR-ABL oncogene monitored in hematopoietic progenitors. Blood 101: 4088–4097.

    Article  CAS  PubMed  Google Scholar 

  • Youn B-S, Jang I-K, Broxmeyer HE, Cooper S, Jenkins NA, Gilbert DJ et al. (1995). A novel chemokine, macrophage inflammatory protein-related protein-2, inhibits colony formation of bone marrow myeloid progenitors. J Immunol 155: 2661–2667.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Cathy Tomastik for editorial assistance, A Pierce (Leukaemia Research Fund Cellular Development Unit, UMIST, Manchester, UK) for the kind gift of FDCP-mix BCR/ABL cells and A Mondino (S Raffaele Scientific Institute, Milano, Italy) for insightful discussion. Giorgio Iotti was supported, in part, by a fellowship of the Fondazione Cassa di Risparmio di Carpi. Maria Rosa Lidonnici was supported, in part, by a fellowship of the American-Italian Foundation for Cancer Research. Francesca Corradini was supported, in part, by a fellowship of the Associazione Italiana Ricerca sul Cancro (AIRC). This work was supported, in part, by NIH Grant PO178890 to B Calabretta. This work is dedicated to the memory of Dr Bice Perussia

Author information

Authors and Affiliations

  1. Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas Jefferson Medical College, Philadelphia, PA, USA

    G Iotti, G Ferrari-Amorotti, M R Lidonnici, M Ronchetti, M Bardini & B Calabretta

  2. Department of Biomedical Sciences, Universitá di Modena e Reggio Emilia, Modena, Italy

    G Iotti, C Rosafio & F Corradini

  3. IFOM, FIRC Institute of Molecular Oncology, Milano, Italy

    G Iotti & F Blasi

  4. Wyeth Genetics Institute, Cambridge, MA, USA

    Y Zhang & R Martinez

Authors
  1. G Iotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G Ferrari-Amorotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Rosafio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F Corradini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M R Lidonnici
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Ronchetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Bardini
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Y Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R Martinez
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. F Blasi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. B Calabretta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B Calabretta.

Additional information

Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Iotti, G., Ferrari-Amorotti, G., Rosafio, C. et al. Expression of CCL9/MIP-1γ is repressed by BCR/ABL and its restoration suppresses in vivo leukemogenesis of 32D-BCR/ABL cells. Oncogene 26, 3482–3491 (2007). https://doi.org/10.1038/sj.onc.1210146

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1210146

Keywords

Search

Advanced search

Quick links